Hypothesis

Humanin and the six SHLPs function as baseline regulators of mitochondrial NAD+ pools, tuning sirtuin activity and metabolic flux without requiring activation of the mitochondrial unfolded protein response (mtUPR). Their organ‑specific expression reflects local NAD+ salvage capacity rather than a stress‑responsive retrograde signal.

Mechanistic Rationale

Cohen’s team identified SHLP1‑6 through mitochondrial genome analysis and detected them in mouse tissues and human cells[1]. Yet the published work lacks quantitative dose‑response data, leaving it unclear whether these peptides rise during stress or are present at steady‑state levels. Centenarians exhibit lower oxidative stress markers without documented elevations of MOTS‑c, humanin, or SHLPs[2]. If SHLPs were strictly stress‑induced, we would expect higher levels in long‑lived individuals experiencing reduced oxidative pressure—a contradiction.

We propose that SHLPs interact with the mitochondrial inner membrane to influence the activity of NAD+‑consuming enzymes such as PARPs and CD38. By subtly altering the NAD+/NADH ratio, they modulate sirtuin‑dependent deacetylation of metabolic enzymes and transcription factors, thereby adjusting oxidative phosphorylation efficiency. This action is constitutive: basal SHLP secretion sets the tonic NAD+ tone, and stress pathways like ATF4/CHOP are engaged only when this tone is overwhelmed.

Organ specificity arises because tissues differ in NAD+ biosynthesis flux (e.g., liver high NAMPT, brain low). SHLP expression patterns could thus mirror the capacity of each organ to buffer NAD+ changes, providing a localized feedback loop that matches peptide supply to metabolic demand.

Testable Predictions

1. Basal SHLP concentrations in wild‑type mice will correlate positively with tissue NAD+/NADH ratios and negatively with PARP activity.
2. Genetic ablation of SHLP2 will lower hepatic NAD+ levels and impair insulin sensitivity, but will not further reduce ATF4/CHOP activation under tunicamycin‑induced ER stress.
3. Pharmacological inhibition of ATF4 (using ISRIB) will abolish the transcriptional response to mtUPR inducers without affecting the metabolic benefits of exogenous SHLP6 administration in cancer cell lines.
4. Centenarian plasma will show SHLP concentrations comparable to, or slightly higher than, age‑matched controls, despite lower oxidative stress markers.

Experimental Approach

• Quantify SHLP1‑6 in mouse liver, muscle, brain, and pancreas using targeted mass spectrometry with isotope‑labeled standards; measure NAD+/NADH, SIRT1 activity, and PARP‑1 auto‑modification in the same samples.
• Generate CRISPR‑KO mice lacking SHLP2; perform insulin tolerance tests and assess hepatic NAD+ levels under fed and fasted conditions.
• Treat SHLP6‑sensitive cancer lines with recombinant SHLP6 ± ISRIB; read out cell viability, ATF4/CHOP western blotting, and Seahorse OCR/ECAR.
• Analyze plasma from the New England Centenarian Study (or equivalent cohort) for SHLP levels using immuno‑PCR; correlate with plasma 8‑iso‑PGF2α and NAD+ metabolites.

Falsification occurs if SHLP loss does not alter basal NAD+/NADH ratios, if ATF4 inhibition abolishes SHLP‑mediated metabolic effects, or if centenarians show markedly reduced SHLP levels despite low oxidative stress. This framework shifts the focus from stress‑induced retrograde signaling to a homeostatic, NAD+‑centric mode of action that can be independently validated across labs and populations.